Elucidating the upstream determinants of GATA6 activation and linking the secretory phenotype of the tumor cells to the underlying genetic landscape could result in further insights into TME immunological niches and ultimately aid in stratifying patients who are most likely to benefit from such novel therapeutic approaches. Here, GATA6 is linked to neoplasm.